aaiPharma Added to Nasdaq Biotechnology Index WILMINGTON, N.C., Nov. 24 /PRNewswire-FirstCall/ -- aaiPharma Inc. , a science-based specialty pharmaceutical company, announced that the Company has been added to the Nasdaq Biotechnology Index effective today, November 24, 2003. "This listing is a testament to aaiPharma's strong financial position and continued execution of the Company's science-based specialty pharmaceutical strategy," said Dr. Philip S. Tabbiner, President and CEO of aaiPharma. Launched in 1993, the Nasdaq Biotechnology Index contains companies that are classified according to the FTSE(TM) Global Classification System as either biotechnology or pharmaceutical. The Nasdaq Biotechnology Index is calculated under a modified capitalization-weighted methodology. All securities in the Index are listed on the Nasdaq National Market and meet minimum requirements, including market value, average daily share volume, and seasoning as a public company. The Index is ranked on a semi-annual basis in May and in November, and serves as the basis for the iShares Nasdaq Biotechnology Index Fund(SM) (IBB). About aaiPharma aaiPharma Inc. is a science-based specialty pharmaceutical company with more than 23 years of drug development experience. Focusing on targeted therapeutic areas, the Company markets a growing portfolio of established branded products and applies innovative technologies to increase the commercial potential of these products. At the same time, aaiPharma's research and development organization is developing a pipeline of products to position the Company for near-term and long-term growth in its targeted therapeutic areas. In addition to developing and marketing its own line of proprietary pharmaceutical products, aaiPharma continues to be a leader in providing contract pharmaceutical development services through its AAI Development Services division. For more information on the Company, please visit us on the web at http://www.aaipharma.com/. DATASOURCE: aaiPharma Inc. CONTACT: media, Andrea L. Johnston, Vice President, Corporate Communications, +1-910-254-7340, or investors, James B. Sloan, Jr., Senior Vice President, Corporate Finance, +1-910-254-7690, both of aaiPharma Inc. Web site: http://www.aaipharma.com/

Copyright